[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68(6):394-424.
[2] Karpiński TM. Role of Oral Microbiota in Cancer Development. Microorganisms. 2019, 7(1):E20.
[3] Chang C, Geng F, Shi X, Li Y, Zhang X, Zhao X, et al. The prevalence rate of periodontal pathogens and its association with oral squamous cell carcinoma. Appl Microbiol Biotechnol. 2019, 103(3):1393-1404.
[4] Park DG, Woo BH, Lee BJ, Yoon S, Cho Y, Kim YD, et al. Serum Levels of Interleukin-6 and Titers of Antibodies Against Porphyromonas gingivalis Could Be Potential Biomarkers for the Diagnosis of Oral Squamous Cell Carcinoma. Int J Mol Sci. 2019, 20(11):E2749.
[5] Wu JS, Zheng M, Zhang M, Pang X, Li L, Wang SS, et al. Porphyromonas gingivalis Promotes 4-Nitroquinoline-1-Oxide-Induced Oral Carcinogenesis With an Alteration of Fatty Acid Metabolism. Front Microbiol. 2018, 9:2081.
[6] Utispan K, Pugdee K, Koontongkaew S. Porphyromonas gingivalis, lipopolysaccharide-induced macrophages modulate proliferation and invasion of head and neck cancer cell lines. Biomed Pharmacother. 2018, 101:988-995.
[7] Groeger S, Jarzina F, Domann E, Meyle J. Porphyromonas gingivalisactivates NFκB and MAPK pathways in human oral epithelial cells. BMC Immunol. 2017, 18(1):1.
[8] Woo BH, Kim DJ, Choi JI, Kim SJ, Park BS, Song JM, et al. Oral cancer cells sustainedly infected with Porphyromonas gingivalis exhibit resistance to Taxol and have higher metastatic potentia. Oncotarget, 2017, 8(29):46981-46992.
[9] Ha NH, Woo BH, Kim DJ, Ha ES, Choi JI, Kim SJ, et al. Prolonged and repetitive exposure to Porphyromonas gingivalis increases aggressiveness of oral cancer cells by promoting acquisition of cancer stem cell properties. Tumour Biol. 2015, 36(12):9947-9960.
[10] Abreu MGL, Kawamoto D, Mayer MPA, Pascoal VDB, Caiaffa KS, Zuza EP, et al. Frequency of Porphyromonas gingivalis fimA in smokers and nonsmokers after periodontal therapy. J Appl Oral Sci. 2019, 27:e20180205.
[11] Nakagawa I, Amano A, Ohara-Nemoto Y, Endoh N, Morisaki I, Kimura S, et al. Identification of a new variant of fimA gene of Porphyromonas gingivalis and its distribution in adults and disabled populations with periodontitis. J Periodontal Res. 2002, 37(6):425-432.
[12] Nagano K, Hasegawa Y, Abiko Y, Yoshida Y, Murakami Y, Yoshimura F. Porphyromonas gingivalis FimA fimbriae: fimbrial assembly by fimA alone in the fim gene cluster and differential antigenicity among fimA genotypes. PLoS One, 2012, 7(9):e43722.
[13] Miura M, Hamachi T, Fujise O, Maeda K. The prevalence and pathogenic differences of Porphyromonas gingivalis fimA genotypes in patients with aggressive periodontitis. J Periodontal Res. 2010, 40(2):147-152.
[14] Amano A, Kuboniwa M, Nakagawa I, Akiyama S, Morisaki I, Hamada S. Prevalence of specific genotypes of Porphyromonas gingivalis fimA and periodontal health status. J Dent Res. 2000, 79(9):1664-1668.
[15] MB Amin, SB Edge, FL Greene, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
[16] Fan X, Peters BA, Min D, Ahn J, Hayes RB. Comparison of the oral microbiome in mouthwash and whole saliva samples. PLoS One, 2018, 13(4):e0194729.
[17] Al-Rawi N, Al-Marzooq F. The Relation between Periodontopathogenic Bacterial Levels and Resistin in the Saliva of Obese Type 2 Diabetic Patients. J Diabetes Res. 2017, 2017:2643079.
[18] Amano A, Nakagawa I, Kataoka K, Morisaki I, Hamada S. Distribution of Porphyromonas gingivalis strains with fimA genotypes in periodontitis patients. J Clin Microbiol. 1999, 37(5):1426-1430.
[19] Moon JH, Shin SI, Chung JH, Lee SW, Amano A, Lee JY. Development and evaluation of new primers for PCR-based identification of type II fimA of Porphyromonas gingivalis. FEMS Immunol Med Microbiol. 2012, 64(3):425-428.
[20] Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990, 215(3):403-410.
[21] Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization[J]. Clin Cancer Res. 2004, 10(21):7252-7259.
[22] Hoppe T, Kraus D, Probstmeier R, et al. Stimulation with Porphyromonas gingivalis enhances malignancy and initiates anoikis resistance in immortalized oral keratinocytes. J Cell Physiol. 2019,234(12):21903-21914.
[23] Chaturvedi P, Singh A, Chien CY, et al. Tobacco related oral cancer[J]. BMJ. 2019,5(365): l2142.
[24] Gogeneni H, Buduneli N, Ceyhan-Öztürk B, et al . Increased infection with key periodontal pathogens during gestational diabetes mellitus[J]. J Clin Periodontol. 2015,42(6):506-512.
[25] Hanaoka Y, Soejima H, Yasuda O, et al. Level of serum antibody against a periodontal pathogen is associated with atherosclerosis and hypertension[J]. Hypertens Res. 2013,36(9):829-833.
[26] Fan X, Alekseyenko AV, Wu J, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study[J]. Gut. 2018,67(1):120-127.
[27] Michaud DS, Izard J, Wilhelm-Benartzi CS, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut[J]. 2013,62(12):1764-1770.
[28] Peters BA, Wu J, Pei Z, et al. Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers[J]. Cancer Res. 2017,77(23):6777-6787.
[29] Gao SG, Yang JQ, Ma ZK, et al. Preoperative serum immunoglobulin G and A antibodies to Porphyromonas gingivalis are potential serum biomarkers for the diagnosis and prognosis of esophageal squamous cell carcinoma[J]. BMC Cancer. 2018,18(1):17.
[30] Gao S, Li S, Ma Z, et al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer[J]. Infect Agent Cancer. 2016,11:3.
[31] Lin X, Wu J, Xie H. Porphyromonas gingivalis minor fimbriae are required for cell-cell interactions. Infect Immun. 2006, 74(10):6011-6015.
[32] Missailidis CG, Umeda JE, Ota-Tsuzuki C, Anzai D, Mayer MP. Distribution of fimA genotypes of Porphyromonas gingivalis in subjects with various periodontal conditions. Oral Microbiol Immunol, 2004, 19(4):224-229.
[33] Amano A, Nakagawa I, Okahashi N, Hamada N. Variations of Porphyromonas gingivalis fimbriae in relation to microbial pathogenesis. J Periodontal Res. 2004, 39(2):136-142.
[34] Nakano K, Kuboniwa M, Nakagawa I, Yamamura T, Nomura R, Okahashi N, et al. Comparison of inflammatory changes caused by Porphyromonas gingivalis with distinct fimA, genotypes in a mouse abscess model. Oral Microbiol Immunol. 2004, 19(3):205-209.
[35] Enersen M, Olsen I, Kvalheim Ø, Caugant DA. fimA genotypes and multilocus sequence types of Porphyromonas gingivalis from patients with periodontitis. J Clin Microbiol. 2008, 46(1):31-42.
[36] Moreno S, Jaramillo A, Parra B, Botero JE, Contreras A. Porphyromonas gingivalis Fim-A genotype distribution among Colombians. Colomb Med (Cali). 2015, 46(3):122-127.
[37] Perez-Chaparro PJ, Rouillon A, Minet J, Lafaurie GI, Bonnaure-Mallet M. fimA genotypes and PFGE profile patterns in Porphyromonas gingivalis isolates from subjects with periodontitis. Oral Microbiol Immunol. 2009, 24(5):423-426.
[38] Castillo-Rojas G, Cerbón MA, López-Vidal Y. Presence of Helicobacter pylori in a Mexican Pre-Columbian Mummy. BMC Microbiol. 2008, 8(1):119.